Ergoteles’s Pacific Biosciences PACB Stock Holding History

Ergoteles’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-79,558	Closed	-$2.03M	–	1505
2021 Q3	$2.03M	Buy	+79,558	New	+$2.36M	0.07%	260

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ergoteles's PACB Position: Q4 2021 in Review

Ergoteles sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 79,558 shares — an estimated $2.03M sold.

Ergoteles first reported a position in PACB in Q3 2021 and held it in 1 quarter. The position peaked at $2.03M in Q3 2021. 256 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

Ergoteles reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 79,558 Pacific Biosciences shares in Q4 2021, an estimated $2.03M.
Ergoteles first reported a position in Pacific Biosciences in Q3 2021 and held it in 1 quarter.
Ergoteles's Pacific Biosciences position peaked at $2.03M in Q3 2021.
256 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.